Skip to main content

Advertisement

SpringerLink
Log in

Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Current guidelines recommend a blood pressure goal of less than 130/80 mm Hg in patients with chronic kidney disease. Considerable epidemiologic observational data, post hoc analyses of clinical trials, and meta-analyses support this goal, particularly in patients with proteinuria. Although prospective clinical trials have not shown a clear benefit, recent data indicate that a longer duration of follow-up may be needed to assess the effects of different blood pressure goals. While we await the results of several ongoing and planned studies in this area, the current recommendations of a blood pressure goal less than 130/80 mm Hg appear reasonable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038–2047.

    Article  PubMed  CAS  Google Scholar 

  2. United States Renal Data System prevalence data. Available at http://www.usrds.org/2006/ref/B_prevalence_06.pdf.

  3. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  4. Plantinga LC, Miller ER 3rd, Stevens LA, et al.: Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999–2006. Hypertension 2009, 54:47–56.

    Article  PubMed  CAS  Google Scholar 

  5. Khosla N, Kalaitzidis R, Bakris GL: The kidney, hypertension, and remaining challenges. Med Clin North Am 2009, 93:697–715.

    Article  PubMed  CAS  Google Scholar 

  6. Kao WH, Klag MJ, Meoni LA, et al.: MYH9 is assoc iated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185–1192.

    Article  PubMed  CAS  Google Scholar 

  7. Kopp JB, Smith MW, Nelson GW, et al.: MYH9 is a majoreffect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175–1184.

    Article  PubMed  CAS  Google Scholar 

  8. Freedman BI, Kopp JB, Winkler CA, et al.: Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN Study. Am J Nephrol 2009, 29:626–632.

    Article  PubMed  CAS  Google Scholar 

  9. Freedman BI, Hicks PJ, Bostrom MA, et al.: Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009, 75:736–745.

    Article  PubMed  CAS  Google Scholar 

  10. Freedman BI, Sedor JR: Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008, 19:2047–2051.

    Article  PubMed  Google Scholar 

  11. Shulman NB, Ford CE, Hall WD, et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989, 13:I80–I93.

    PubMed  CAS  Google Scholar 

  12. Walker WG, Neaton JD, Cutler JA, et al.: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992, 268:3085–3091.

    Article  PubMed  CAS  Google Scholar 

  13. Perry HM Jr, Miller JP, Fornoff JR, et al.: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995, 25:587–594.

    PubMed  Google Scholar 

  14. Klag MJ, Whelton PK, Randall BL, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13–18.

    Article  PubMed  CAS  Google Scholar 

  15. Mailloux LU: Hypertension in chronic renal failure and ESRD: prevalence pathophysiology and outcomes. Semin Nephrol 2001, 21:146–156.

    Article  PubMed  CAS  Google Scholar 

  16. Mailloux LU, Levey AS: Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998, 32:S120–S141.

    Article  PubMed  CAS  Google Scholar 

  17. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.

    Google Scholar 

  18. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria retinopathy and strokes. Kidney Int 2002, 61:1086–1097.

    Article  PubMed  Google Scholar 

  19. Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163:1555–1565.

    Article  PubMed  Google Scholar 

  20. Pohl MA, Blumenthal S, Cordonnier DJ, et al.: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027–3037.

    Article  PubMed  CAS  Google Scholar 

  21. Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control proteinuria and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244–252.

    PubMed  CAS  Google Scholar 

  22. Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877–884.

    Article  PubMed  CAS  Google Scholar 

  23. Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431.

    Article  PubMed  CAS  Google Scholar 

  24. Sarnak MJ, Greene T, Wang X, et al.: The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005, 142:342–351.

    PubMed  Google Scholar 

  25. Appel LJ, Wright JT Jr, Greene T, et al.: Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008, 168:832–839.

    Article  PubMed  CAS  Google Scholar 

  26. de Galan BE, Perkovic V, Ninomiya T, et al.: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883–892.

    Article  PubMed  CAS  Google Scholar 

  27. Schrier R, McFann K, Johnson A, et al.: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002, 13:1733–1739.

    Article  PubMed  Google Scholar 

  28. Ruggenenti P, Perna A, Loriga G, et al.: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre randomised controlled trial. Lancet 2005, 365:939–946.

    Article  PubMed  Google Scholar 

  29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  30. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275–279.

    Article  PubMed  CAS  Google Scholar 

  31. Parving HH, Hommel E, Smidt UM: Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988, 297:1086–1091.

    Article  PubMed  CAS  Google Scholar 

  32. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497–504.

    Article  PubMed  CAS  Google Scholar 

  33. Bjorck S, Mulec H, Johnsen SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339–343.

    Article  PubMed  CAS  Google Scholar 

  34. Bursztyn M, Kobrin I, Fidel J, Ben-Ishay D: Improved kidney function with cilazapril in hypertensive type II diabetics with chronic renal failure. J Cardiovasc Pharmacol 1991, 18:337–341.

    Article  PubMed  CAS  Google Scholar 

  35. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999, 131:660–667.

    PubMed  CAS  Google Scholar 

  36. Mosconi L, Ruggenenti P, Perna A, et al.: Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl 1996, 55:S91–S93.

    PubMed  CAS  Google Scholar 

  37. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive normoalbuminuric patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med 1998, 128:982–988.

    PubMed  CAS  Google Scholar 

  38. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156:286–289.

    Article  PubMed  CAS  Google Scholar 

  39. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  40. Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.

    Article  PubMed  CAS  Google Scholar 

  41. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  42. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  43. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  44. Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.

    Article  PubMed  CAS  Google Scholar 

  45. Zucchelli P, Zuccala A, Borghi M, et al.: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992, 42:452–458.

    Article  PubMed  CAS  Google Scholar 

  46. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992, 5:423–430.

    PubMed  CAS  Google Scholar 

  47. van Essen GG, Apperloo AJ, Rensma PL, et al.: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 1997, 63:S58–S62.

    PubMed  Google Scholar 

  48. Hannedouche T, Landais P, Goldfarb B, et al.: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994, 309:833–837.

    PubMed  CAS  Google Scholar 

  49. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995, 111:184–192.

    PubMed  CAS  Google Scholar 

  50. Himmelmann A, Hansson L, Hansson BG, et al.: ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995, 4:85–90.

    Article  PubMed  CAS  Google Scholar 

  51. Ihle BU, Whitworth JA, Shahinfar S, et al.: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996, 27:489–495.

    Article  PubMed  CAS  Google Scholar 

  52. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939–945.

    Article  PubMed  CAS  Google Scholar 

  53. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric nondiabetic nephropathy. Lancet 1997, 349:1857–1863.

    Article  Google Scholar 

  54. Ruggenenti P, Perna A, Gherardi G, et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359–364.

    Article  PubMed  CAS  Google Scholar 

  55. Bianchi S, Bigazzi R, Baldari G, Campese VM: Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol 1991, 11:131–137.

    Article  PubMed  CAS  Google Scholar 

  56. Okamura M, Kanayama Y, Negoro N, et al.: Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. Contrib Nephrol 1991, 90:161–165.

    PubMed  CAS  Google Scholar 

  57. Aurell M, Bengtsson C, Bjorck S: Enalapril versus metoprolol in primary hypertension-effects on the glomerular filtration rate. Nephrol Dial Transplant 1997, 12:2289–2294.

    Article  PubMed  CAS  Google Scholar 

  58. Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73–87.

    PubMed  CAS  Google Scholar 

  59. Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease High Blood Pressure Research Clinical Cardiology and Epidemiology and Prevention. Hypertension 2003, 42:1050–1065.

    Article  PubMed  CAS  Google Scholar 

  60. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356–360.

    PubMed  CAS  Google Scholar 

  61. Gerstein HC, Mann JF, Yi Q, et al.: Albuminuria and risk of cardiovascular events death and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.

    Article  PubMed  CAS  Google Scholar 

  62. Muntner P, He J, Hamm L, et al.: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002, 13:745–753.

    PubMed  Google Scholar 

  63. Perkovic V, Verdon C, Ninomiya T, et al.: The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008, 5:e207.

    Article  PubMed  CAS  Google Scholar 

  64. Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296–1305.

    Article  PubMed  CAS  Google Scholar 

  65. Anavekar NS, McMurray JJ, Velazquez EJ, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285–1295.

    Article  PubMed  CAS  Google Scholar 

  66. Rahman M, Pressel S, Davis BR, et al.: Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006, 144:172–180.

    PubMed  Google Scholar 

  67. Wattanakit K, Coresh J, Muntner P, et al.: Cardiovascular risk among adults with chronic kidney disease with or without prior myocardial infarction. J Am Coll Cardiol 2006, 48:1183–1189.

    Article  PubMed  Google Scholar 

  68. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112–S119.

    Article  PubMed  CAS  Google Scholar 

  69. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

    Article  PubMed  Google Scholar 

  70. Berl T, Hunsicker LG, Lewis JB, et al.: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005, 16:2170–2179.

    Article  PubMed  CAS  Google Scholar 

  71. Ogihara T, Saruta T, Rakugi H, et al.: Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial. Hypertens Res 2009, 32:248–254.

    Article  PubMed  Google Scholar 

  72. Pogue V, Rahman M, Lipkowitz M, et al.: Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009, 53:20–27.

    Article  PubMed  CAS  Google Scholar 

  73. Townsend RR: Analyzing the radial pulse waveform: narrowing the gap between blood pressure and outcomes. Curr Opin Nephrol Hypertens 2007, 16:261–266.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA

    Mahboob Rahman

Authors
  1. Bassam G. Abu Jawdeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahboob Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahboob Rahman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abu Jawdeh, B.G., Rahman, M. Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?. Current Science Inc 11, 363–367 (2009). https://doi.org/10.1007/s11906-009-0060-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-009-0060-3

Keywords

Search

Navigation